



National Institute
of Mental Health



CEPI



Vaccinopolis
University of Antwerp

Enabling the Evaluation of COVID-19 Vaccines with Correlates of Protection Vaccinopolis University of Antwerp, Belgium February 16 - 17, 2023



Robbert van der Most, PhD

Vice-President Translational Science

55131 Mainz, Germany

BioNTech

Address: An der Goldarube 12, Mainz

Tel: +49-151 22120668

E-mail: robbert.vandermost@biontech.de

After obtaining his PhD at Leiden University (NL) in 1994 on coronavirus RNA replication, Robbert joined Dr Rafi Ahmed's lab at UCLA (USA) to conduct postdoctoral research on the immunology of (chronic) viral infection. Following postdoctoral work at Caltech, he then went to Dr Ahmed's laboratory at Emory University. Returning to the Netherlands in 2000, he worked on RSV vaccines and enhanced disease models. In 2004, he joined the Tumour Immunology Group at the University of Western Australia, working on mesothelioma. He made the change to industry by joining GSK Vaccines in Belgium in 2008, in roles of increasing responsibility. In 2021, he left GSK to join CEPI, followed by a change to BioNTech in 2022, in the currently held position of VP Translational Science, located in Germany and being responsible for biomarker strategy across infectious disease projects. Robbert has published ~100 peer-reviewed articles.

